Recombinagenic and mutagenic activities of fluoroquinolones in Drosophila melanogaster

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 742, Issue 1-2, 2012, Pages 43-47

  Thomé, Simone ^a   Bizarro, Cassiane Rosa ^a   Lehmann, Mauricio ^a   Abreu, Bianca Regina Ribas de ^a   Andrade, Heloisa Helena Rodrigues de ^c   Cunha, Kênya Silva ^b   Dihl, Rafael Rodrigues ^a  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Ciprofloxacin; Enrofloxacin; Genotoxicity; Homologous recombination; Norfloxacin; SMART

Indexed keywords

CIPROFLOXACIN; ENROFLOXACIN; NORFLOXACIN;

ARTICLE; DROSOPHILA MELANOGASTER; DRUG ACTIVITY; FREQUENCY ANALYSIS; GENETIC ANALYSIS; GENOTOXICITY; HETEROZYGOSITY LOSS; HETEROZYGOTE; MITOTIC RECOMBINATION; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; SOMATIC MUTATION AND RECOMBINATION TEST; TOXICITY TESTING;

ANIMALS; ANTI-BACTERIAL AGENTS; DROSOPHILA MELANOGASTER; FLUOROQUINOLONES; HOMOLOGOUS RECOMBINATION; MUTAGENICITY TESTS; MUTAGENS;

DROSOPHILA MELANOGASTER; EUKARYOTA; PROKARYOTA;

EID: 84856113193     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.11.012     Document Type: Article

References (38)

1. Hu J., Wang W., Zhu Z., Chang H., Pan F., Lin B. Quantitative structure-activity relationship model for prediction of genotoxic potential for quinolone antibacterials. Environ. Sci. Technol. 2007, 41:4806-4812.
2. Chee-Sanford J.C., Aminov R.I., Krapac I.J., Garrigues-Jeanjean N., Mackie R.I. Occurrence and diversity of tetracycline resistant genes in lagoons and groundwater underlying two swine production facilities. Appl. Environ. Microbiol. 2001, 67:1494-1502.
3. Kim S.C., Carlson K. Temporal and spatial trends in the occurrence of human and veterinary antibiotics in aqueous and river sediment matrices. Environ. Sci. Technol. 2007, 41:50-57.
4. Davies I. Medicine - bacteria on the rampage. Nature 1996, 383:219-220.
5. Ihrke P.J., Papich M.G., Demanuelle T.C. The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 1999, 10:193-204.
6. Suh B., Lorber B. Quinolones. Med. Clin. North. Am. 1995, 79:869.
7. Khodursky A.B., Cozzarelli N.R. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 1998, 273:668-677.
8. Heddle J.G., Barnard F.M., Wentzell L.M., Maxwell A. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action. Nucleosides. Nucleotides Nucleic Acids 2000, 19:1249-1264.
9. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.
10. Herbold B.A., Brendler-Schwaab S.Y., Ahr H.J. Ciprofloxacin: in vivo genotoxicity studies. Mutat. Res. 2001, 498:193-205.
11. Bishop A.J., Schiestl R.H. Role of homologous recombination in carcinogenesis. Exp. Mol. Pathol. 2003, 74:94-105.
12. Andrade H.H.R., Reguly M.L., Lehmann M. Wing somatic mutation and recombination test. Drosophila Cytogenetics Protocols 2004, 389-412. Humana Press, New Jersey. D.S. Henderson (Ed.).
13. Lindsley D.L., Zimm G.G. The Genome of Drosophila melanogaster. Academic Press 1992.
14. Frei H., Würgler F.E. Statistical methods to decide whether mutagenicity test data from Drosophila assays indicate a positive, negative, or inconclusive result. Mutat. Res. 1988, 203:297-308.
15. Kastenbaum M.A., Bowman K.O. Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 1970, 9:527-549.
16. Cunha K.S., Reguly M.L., Graf U., Andrade H.H.R. Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster. Mutagenesis 2001, 16:79-84.
17. Tiburi M., Reguly M.L., Schwartsmann G., Cunha K.S., Lehmann M., Andrade H.H.R. Comparative genotoxic effect of vincristine, vinblastine, and vinorelbine in somatic cells of Drosophila melanogaster. Mutat. Res. 2002, 51:141-149.
18. Frei H., Würgler F.E. Induction of somatic mutation and recombination by four inhibitors of eukaryotic topoisomerases assayed in the wing spot test of Drosophila melanogaster. Mutagenesis 1996, 11:315-325.
19. Frei H., Würgler F.E. Optimal experimental design and sample size for the statistical evaluation of data from somatic mutation and recombination tests (SMART) in Drosophila. Mutat. Res. 1995, 334:247-258.
20. Lehmann M., Franco A., Vilar K.S.P., Reguly M.L., Andrade H.H.R. Doxorubicin and two of its analogues are preferential inducers of homologous recombination compared with mutational events in somatic cells of Drosophila melanogaster. Mutat. Res. 2003, 539:167-175.
21. Holden H.E., Barrett J.F., Huntington C.M., Muehlbauer P.A., Wahrenburg M.G. Genetic profile of a naladixic acid analog: a model for the mechanism of sister chromatid exchange induction. Environ. Mol. Mutagen. 1989, 13:238-252.
22. McQueen C.A., Way B.M., Queener S.M., Schluter G., Williams G.M. Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics. Toxicol. Appl. Pharmacol. 1991, 111:255-262.
23. Ciaravino V., Suto M.J., Thiess J.C. High capacity in vitro micronucleus assay for assessment of chromosome damage: results with quinolone/naphthyridone antibacterial. Mutat. Res. 1993, 298:227-236.
24. Kashida Y., Sasaki Y.F., Ohsawa K., Yokohama N., Takahashi A., Watanabe T., Mitsumori K. Mechanistic study on flumequine hepatocarcinogenicity focusing on DNA damage in mice. Toxicol. Sci. 2002, 69:317-321.
25. Hayasaki Y., Itoh S., Kato M., Furuhama K. Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101. Toxicol. In Vitro 2006, 20:342-346.
26. Itoh T., Mitsumori K., Kawaguchi S., Sasaki Y.F. Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test. Mutat. Res. 2006, 603:135-144.
27. Barrett J.F., Gootz T.D., McGuirk P.R., Farrell C.A., Sokolowski S.A. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob. Agents Chemother. 1989, 33:1697-1703.
28. Hoshino K., Sato K., Une T., Osada Y. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob. Agents Chemother. 1989, 33:1816-1818.
29. Curry P.T., Kropko M.L., Garvin J.R., Fiedler R.D., Theiss J.C. In vitro induction of micronuclei and chromosome aberrations by quinolones: possible mechanisms. Mutat. Res. 1996, 352:143-150.
30. Mukherjee A., Sen S., Agarwal K. Ciprofloxacin: mammalian DNA topoisomerase type-II poison in vivo. Mutat. Res. 1993, 301:87-92.
31. Gorla N., Garcia Ovando H., Larripa I. Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin. Toxicol. Lett. 1999, 104:43-48.
32. Cester C.C., Toutain P.L. A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. Pharm. Sci. 1997, 86:148-155.
33. Kaartinen L., Salonen M., Alli L., Pyörälä S. Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J. Vet. Pharmacol. Ther. 1995, 18:357-362.
34. Osheroff N., Zechiedrich E.L., Gale K.C. Catalytic function of topoisomerase II. BioEssays 1991, 13:269-275.
35. Liu Q., Wang J.C. Similarity in the catalysis of DNA breakage and rejoining by type IA and IIA DNA topoisomerases. Proc. Natl. Acad. Sci. 1999, 96:881-886.
36. Heisig P. Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagenesis 2009, 24:465-469.
37. Rothstein R., Michel B., Gangloff S. Replication fork pausing and recombination or " gimme a break" Genes Dev. 2000, 14:1-10.
38. Lehmann M., de Vilar K.##S., Franco A., Reguly M.L., Andrade H.H.R. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ. Mol. Mutagen. 2004, 43:250-257.